Telomir Pharmaceuticals' Telomir-1 small molecule shows promising results in a small study on senior dogs, including one with terminal cancer in remission.

Telomir Pharmaceuticals, a longevity science company, reports positive results from a small study with two senior dogs using its Telomir-1 small molecule. The treatment led to significant improvements in health and vitality, including one dog experiencing complete remission of terminal cancer. While in preclinical development and not yet tested on humans, the results are encouraging for potential future applications in humans.

August 20, 2024
6 Articles